2010

BioAlliance Pharma announces new opportunities for its Patented Lauriad™ mucoadhesive technology

New collaborative programs BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both “Clusters of excellence”, Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects…read more →

BioAlliance Pharma presents preclinical and phase I clinical results with its AMEP® biotherapy for metastatic melanoma

At the “Electrochemotherapy 1st International Users’ Meeting” (Bologna, Italy, November 19-20, 2010) BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP® biotherapy at the “Electrochemotherapy 1st International Users’ Meeting” (Bologna, Italy, November 19-20, 2010). The AMEP® biotherapy is…read more →

BioAlliance Pharma presents pharmacokinetic results of its Sitavir® (acyclovir Lauriad®)

At the FIP Pharmaceutical Sciences World Congress (PSWC) 2010 in association with the AAPS Annual Meeting and Exposition (November 14-18, 2010, New Orleans, Louisiana, USA) BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, presented the results of the pharmacokinetic study on its Sitavir® (acyclovir Lauriad® 50mg), developed for the…read more →

The structure of BioAlliance Pharma’s turnover for Q3 2010 reflects the dynamism of the company’s American and European collaborations

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a consolidated turnover of €0.9 million for the third quarter of 2010. This recurrent turnover mainly corresponds to revenues received for Loramyc®/Oravig® sales by the company’s international licensing partners. In line with the announcements made in late August, Oravig®…read more →

Dismissal of the civil action filed by Eurofins against BioAlliance in the United States confirmed by the US court of appeals

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, announces that the United States Court of Appeals for the Third Circuit has confirmed the Federal District Judge’s dismissal of the US civil action filed by Eurofins against BioAlliance Pharma and one of its former executives. In addition to finding that…read more →

BioAlliance Pharma will participate in BioPartnering EuropeTM Conference (London, 10-12 October, 2010)

BioAlliance Pharma SA (Euronext Paris -BIO), a company dedicated to the supportive care and treatment of cancer patients, will participate in the 18th BioPartnering EuropeTM Conference (London, 10-12 October, 2010). This international annual conference is dedicated to meetings between the various players in the pharma/biotech area. BioAlliance’s management team will present its development strategy and the significant advances that were…read more →

BioAlliance Pharma staff to participate in the Odyssea breast cancer charity fun run

A team from BioAlliance Pharma SA (Euronext Paris –BIO) will participate in the Odyssea charity fun run on Sunday October 3rd, at Bois de Vincennes, Paris, to the benefit of fight against breast cancer. BioAlliance Pharma builds up its growth on innovation dedicated to the treatment of cancer patients and supportive care. The company’s employees share this commitment and have…read more →

BioAlliance Pharma announces the grant of its European acyclovir Lauriad® patent

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of a European patent protecting its product acyclovir Lauriad®. This patent is now validated in all European countries; this first patent validation is a major step and the procedures up to the grant are ongoing in the…read more →

Acyclovir Lauriad®: US registration file submission planned end-2011

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announces that the US Food and Drug Administration (FDA) considers the positive results of the pivotal phase III study with acyclovir Lauriad® acceptable to submit a 505(b)(2) New Drug Application of the product in the United States. Acyclovir Lauriad®, BioAlliance…read more →

Consolidated accounts for the first semester of 2010

- Significant revenues – Net profit for the first semester reflecting the contribution of licensing agreements – Strongly reinforced cash position BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today presented its consolidated half-year accounts to June 30, 2010. The first half of 2010 was marked by two major…read more →

BioAlliance Pharma announces the launch of Oravig® on the US market by its commercial partner, Strativa/Par Pharmaceutical

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announces the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE:PRX). With…read more →

Changes on BioAlliance Pharma general management

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announces the resignation of Gilles Avenard MD. as Board Member and Deputy Chief Executive Officer, in charge of R&D. Pierre Attali MD., who has been serving BioAlliance Pharma as Chief Medical Officer for several years is today appointed Chief Operating…read more →

A record turnover for Q2 2010 reflecting the successful US FDA approval

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a turnover of €15.2 million for the second quarter of 2010 versus €1.5 million in Q2 2009. Turnover and Cash This dramatic increase is directly linked to the successful approval of Loramyc® in the US under the brand name…read more →

Acyclovir Lauriad®: European registration file submission planned for mid-2011

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced submission mid-2011 of its acyclovir Lauriad® European registration dossier, upon advice of the Health Authorities. Acyclovir Lauriad® is BioAlliance Pharma second product using the Lauriad® technology and has been developed for the treatment of recurrent herpes labialis in immunocompetent…read more →